B-Cell Chronic Lymphocytic Leukemia Clinical Trial Initiated With Argos Therapeutics, Inc.'s AGS-005 Personalized Immunotherapy

DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced that dosing has been initiated in a Phase 1/2 clinical trial to test the activity and safety of AGS-005 in B-cell chronic lymphocytic leukemia (CLL). AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient’s immune system to target and destroy the patient’s cancer cells.
MORE ON THIS TOPIC